Ella Zhang on biotech
From Ella Zhang and Alex Odagiu YZi Labs | theCUBE + NYSE Wired: Crypto Trailblazers · · SiliconANGLE theCUBE
“One of the biggest problems we see in biotech is that biomarker and biodata are siloed in hospitals, clinics, universities, and labs. We aim to leverage blockchain technology to securely aggregate this data for AI training without disclosing personal information, combining security and privacy.”
On , Ella Zhang, Head at Binance Labs, spoke about biotech during Ella Zhang and Alex Odagiu YZi Labs | theCUBE + NYSE Wired: Crypto Trailblazers on SiliconANGLE theCUBE.
About Ella Zhang
Ella Zhang, managing partner and head of YZi Labs (formerly Binance Labs), discussed the firm's rebranding and expanded focus during an August 2025 appearance on theCUBE + NYSE Wired. She stated that the organization rebranded from Binance Labs to YZi Labs to broaden its scope from Web3 to include Web3 plus AI and biotech, describing this as being "at the intersection of the explosion of AI and the combination of AI and Web3 together to advance humanity." Zhang outlined the firm's three main pillars: incubation, direct investment, and liquid strategy, noting that they provide mentorship from figures including CZ and Vitalik, initial funding, and support from early stages to IPO. Zhang also commented on stablecoin adoption, describing three phases: on-chain trading, yield distribution, and now payments and cross-border capital flows, adding that regulatory clarity in the US is driving mainstream adoption. She noted that many countries are building their own stablecoins and paying attention to frameworks like the Genius Act. Regarding YZi Labs' investment approach, Zhang said the firm does not promise token listings when incubating projects, instead encouraging founders to focus on product-market fit before launching tokens. She emphasized that the firm is "open-minded" and "love[s] really crazy ideas," backing founders regardless of what they are building.